John Bishop, Ph.D.

John has served as Ardelyx’s Chief Technical Operations Officer since July of 2025, bringing more than 30 years of experience leading technical operations, quality assurance and Chemistry, Manufacturing, and Controls (CMC) regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization.

Prior to Ardelyx, John held the role of Chief Technology Officer at Lyra Therapeutics, where he was responsible for CMC development activities and the build out of a manufacturing facility to support the company as they moved toward commercialization. John also served as Chief Technology Officer at Forma Therapeutics (acquired by Novo Nordisk) from 2017 to 2021. Previously, he held CMC leadership positions Epizyme, Genocea Biosciences, Momenta Pharmaceuticals, Millennium Pharmaceuticals (now Takeda), DuPont Merck Pharmaceutical Company and Alcon Laboratories.

John earned Bachelor degrees in chemistry and German from Tufts University, a doctoral degree in organic chemistry from University of California, Berkeley, and a Master of Business Administration from Northeastern University.

“Call me Ishmeal.”

-Herman Melville